BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Commences Buyback of 1M Preferred Class D Shares

November 29, 2023 14:18:39

Branded Legacy (OTC: BLEG), a pioneer in the biotechnology and wellness industries, announced its strategic decision to buy back and retire 1,000,000 Preferred Class D Shares. The significant move protects against a conversion ratio of 1 Preferred Class D Share to 100 Common Unrestricted shares, marking a pivotal step in enhancing shareholder value and simplifying Branded Legacy’s share structure by preventing these shares from entering the market. “The buyback and retirement of these Preferred Class D Shares is a strategic move to reinforce our shareholders’ value by preventing dilution,” said Branded Legacy CEO David Oswald. “We are committed to enhancing the appeal of our stock and ensuring a solid foundation for our company’s future.”

To view the full press release, visit https://ibn.fm/F1UeB

About Branded Legacy Inc.

Branded Legacy is a leading biotech organization focused on advancing scientific innovation and improving global health care. With a strong emphasis on research and development, Branded Legacy strives to develop cutting-edge solutions to address unmet medical needs. The company’s robust intellectual property portfolio and state-of-the-art facilities enable it to drive innovation, protect its advancements and maintain a competitive edge in the market. Through strategic partnerships and alliances, Branded Legacy aims to leverage synergies and expand its reach to positively impact the lives of patients worldwide. For more information, visit the company’s website at https://BrandedLegacy.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN